Drug
HS 10517 Dose 1
HS 10517 Dose 1: highest development phase Phase 1/2, developed by Hansoh Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Hansoh Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| HS-10517 Dose 1 NCT05779579 | Phase 1/2 | COVID-19 |
Latest
No recent events.
Follow HS 10517 Dose 1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.